Molecular structure of AP 24534, CAS Number: 943319-70-8
AP 24534 (CAS 943319-70-8)
See product citations (2)
Alternate Names:
Ponatinib
Application:
AP 24534 is a Bcr-Abl (Bcr and c-Abl fusion), FGFR, and Flk-1 inhibitor
CAS Number:
943319-70-8
Purity:
≥98%
Molecular Weight:
532.57
Molecular Formula:
C29H27F3N6O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
AP 24534 is a small molecule, multi-target kinase inhibitor known to potently inhibit Bcr-Abl (the fusion protein of Bcr and c-Abl), Flk-1(VEGFR2) and FGFR. It also exhibits inhibitory activity against PDGFRα, c-Src and c-Kit. AP 24534 inhibits the proliferation of mutant FLT3-positive cells (IC50 of 13 nM), which inhibits mutant FLT3 phosphorylation (IC50 of 1 nM) and the proliferation of Bcr-Abl1 T315I-positive Ba/F3 cells with an IC50 of 8 nM.
AP 24534 (CAS 943319-70-8) References
- A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. | Cortes, JE., et al. 2013. N Engl J Med. 369: 1783-96. PMID: 24180494
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. | Jabbour, E., et al. 2015. Lancet Oncol. 16: 1547-1555. PMID: 26432046
- Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. | Sasaki, K., et al. 2016. Cancer. 122: 3650-3656. PMID: 27479888
- Ponatinib: A Review of Efficacy and Safety. | Massaro, F., et al. 2018. Curr Cancer Drug Targets. 18: 847-856. PMID: 28969556
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. | Cortes, JE., et al. 2018. Blood. 132: 393-404. PMID: 29567798
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. | Jabbour, E., et al. 2018. Lancet Haematol. 5: e618-e627. PMID: 30501869
- Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. | Saussele, S., et al. 2020. Acta Haematol. 143: 217-231. PMID: 31590170
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. | Maiti, A., et al. 2020. Acta Haematol. 143: 567-573. PMID: 32289808
- Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. | Couturier, MA., et al. 2021. Leuk Lymphoma. 62: 620-629. PMID: 33153370
- Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. | Cortes, J., et al. 2021. Blood. 138: 2042-2050. PMID: 34407543
- INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. | Martinelli, G., et al. 2022. Blood Adv. 6: 1742-1753. PMID: 34649276
- Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Ribera, JM., et al. 2022. Blood Adv. 6: 5395-5402. PMID: 35675590
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. | Jabbour, E., et al. 2023. Lancet Haematol. 10: e24-e34. PMID: 36402146
- Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation. | Tousif, S., et al. 2023. Circ Res. 132: 267-289. PMID: 36625265
- Ponatinib-Induced Cerebrovascular Accident (CVA). | Azad, F., et al. 2022. Cureus. 14: e32383. PMID: 36632247
Inhibitor of:
3100002L24Rik, AA987161, Abin-1, Abl, AFAP-1L1, AKIP, ALG11, AML-2, BAALC, BC055004, Bcr, Bek, bFGF, Blk, BSPH1, BTF3, c-Abl, c-Kit, c-Src, Cbl-3, CD45, CLEC-2B, CNIH2, CNK1, Cnpy1, Consortin, CXorf64, DDR2, Dok-6, EFR3A, EG668419, FAK, FAM184A, FAM75C2, FEM-3, Fer, FGF-2, FGFR, FGFR-4, Fibroblast Growth Factor (FGF), FIGNL1, FIP1L1, Flg, Flk-1, Flt-3/Flk-2, FRRS1, GFR-1, Gm447, Gm5894, GPR172C, Hck, IRR, Kar9, KHS, KIR2DS4, KRAP, Lck BP-1, LTK, MGA, MOX-1, NET-2, NET-4, NOK, NUCKS, Olfr541, Olr1059, Olr1063, Olr1064, Olr1126, Olr1206, Olr1220, Olr1231, Olr1259, Olr1320, Olr1384, Olr1397, Olr1560, Olr157, Olr1576, Olr1622, Olr1641, Olr170, Olr223, Olr354, Olr361, Olr484, Olr516, Olr517, Olr530, Olr540, Olr714, Olr72, Olr744, Olr83, Olr889, Olr951, p-Tyr, PDGF-A, PDGFR, PDGFR-alpha, PDGFR-beta, PRAMEF21, Protein tyrosine phosphatase receptor (PTPR), PTPκ, PTPRQ, Ran BP-5, RBMXL3, Ret, RETL2, RICK, RIPK, RKIP, Rse, RUSC2, SEF14, SH3PXD2B, Sin, Slap, Sm D1, Srb4, SUP, TAB, TEL, TLCD1, TM, TNK1, Txk, VSIG10L, and Zfp804b.Activator of:
β-FR, ACK, Bcr, MLKL, PRAT4B_Cnpy4, and Ran BP-5.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AP 24534, 10 mg | sc-362710 | 10 mg | $175.00 | |||
AP 24534, 50 mg | sc-362710A | 50 mg | $983.00 |